Antibe Therapeutics has been developing otenaproxesul, a "miracle drug" that, at least in early trials, controlled both pain and inflammation -- but without the side effects of NSAID drugs. However, the company hit a snag and is now going in a different direction. Will it succeed?
I've been following (and writing about) Antibe Therapeutics' otenaproxesul, an atypical NSAID without the GI toxicity of Aleve or Advil, since early 2020. It's been nothing but good news. Until now. Otenaproxesul caused a substantial jump in liver enzymes in some clinical trial participants. Can the company overcome this? Wall Street sure doesn't think so.
Antibe Therapeutics is developing a badly-needed new class of anti-inflammatory and analgesic NSAIDs that seem to be much easier on the stomach. The FDA just approved the company's IND for otenaproxesul while the drug has already undergone Phase 2 trials in Canada and is gearing up for Phase 3. Not your typical path for drug development, but whatever works is just fine.
Among the unpleasant effects of COVID is a whopping portion of aches and pains. Whether there is anything you can take to feel better -- for example, Advil -- is not clear. But two, large retrospective studies seem to give the thumbs-up to NSAIDs.
It's no secret that NSAIDs come with a host of side effects. But how often? And how bad are they? A presentation at the 2020 PAINWeek Conference gives us some numbers. If taken at face value they are horrifying.
In March I wrote about Phase IIa results of a novel NSAID-like drug ATB-346 (now called otenaproxesul), which is structurally and functionally similar to naproxen (Aleve). But the non-opioid drug lacks its gastrointestinal side effects, especially ulcers. Now Phase IIb results are in and it still looks good. Will it become the first member of a novel class of pain drugs? We could sure use it. A summary of the company's report to shareholders.
When I wrote about "Magic Aleve" -- a derivative of Aleve/naproxen that appears to be both G.I.-friendly and a more potent analgesic/antiinflammatory than Aleve itself -- a number of questions arose. Dr. John Wallace, CSO of Antibe, which is developing the drug called ATB-346, kindly agreed to answer them.
There hasn't been a material advance in the pharmacological treatment of pain since the 1890s, when heroin and aspirin were invented. That may change if an experimental drug being developed by a Toronto-based drug company keeps performing in advanced clinical trials. This could be huge.
Opioid prohibition spares no one, but the elderly are especially vulnerable. If they're in pain, chances are that they will be sent out of their physician's office with nothing more than Tylenol, which is just about useless. It almost happened to my mother. Yours may not be so fortunate.
The pain relief counter in your pharmacy can be a confusing place ... enough so to give you a headache. But actually, it can all be very simple. There are four over-the-counter painkillers, some of which can be taken together and some of which can't. Here's the scoop, presented in a way that's easy to swallow.
Acetaminophen has become the go-to analgesic for many painful conditions. And when used appropriately, it can be effective for headaches and fever reduction. But it's not useful for inflammatory conditions like arthritis, and it can have a significant downside if used in excess.
A systematic review of controlled clinical trials reveals that opioid analgesics are not superior to non-steroidal anti-inflammatory drugs, or NSAIDs, in treating the pain associated with knee osteoarthritis.